ClinicalTrials.gg
RecruitingNCT05875168Updated Oct 15, 2026

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

A Phase 1/2 interventional study of DS-3939a in Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Daiichi Sankyo. Recruiting at 61 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Daiichi Sankyo · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 2 months later.
Updated Oct 15, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
590
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Neoplasm Metastasis by Daiichi Sankyo — 3 open to participants now, 6 under way, 1 of them phase 3. Neoplasm Metastasis · Daiichi Sankyo.

Planned enrollment
Largest of 16
590 · median 87
Started
2023
the only one that year
Phase 1/2
2 of 17
1 open now
Registered
14th of 17
by date

Among the 17 studies in Neoplasm Metastasis by Daiichi Sankyo, this one has the largest planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 1/2, and was the 14th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

3 of the 17 studies in Neoplasm Metastasis by Daiichi Sankyo are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Neoplasm Metastasis by Daiichi Sankyo, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.

Read the detailed description

DS-3939a is an antibody drug conjugate (ADC) being developed for the treatment of malignant tumors. This is a first-in-human, dose-escalating clinical study divided into 2 parts: the Dose Escalation Part (Part 1) and the Dose Expansion Part (Part 2).

03

Conditions studied

  • Advanced Solid Tumor
  • Metastatic Solid Tumor

Browse trials for

Keywords

  • DS-3939a
  • Advanced/metastatic solid tumors
  • Antibody drug conjugate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign and date the main Form (ICF).
  • Has a ≥50% by either an echocardiogram or multigated acquisition within 28 days of enrollment.
  • Has adequate organ function.
  • based on V1.1.
  • performance status score of 0 or 1.

Additional inclusion criteria for Part 1

  • Has a or cytologically documented locally advanced, , or unresectable solid malignant tumors.

Additional inclusion criteria for Part 2

  • Has a histologically or cytologically documented locally advanced, metastatic, or unresectable cancer meeting the protocol criteria
  • Is able to provide either of the following baseline tumor samples:

    1. Fresh tumor samples meeting either of the following requirements that were obtained during the Main Screening or Tissue Screening Period, or

      • Fresh core needle biopsy sample
      • Fresh biopsy samples obtained with forceps or cryobiopsy, such as bronchoscopic or transbronchial lung biopsy, or other procedures as long as the sample amount is equivalent to core needle biopsy and processing after sample collection follows the procedure described in the Study Laboratory Manual.
    2. FFPE tumor tissue samples obtained by biopsy or surgery performed within 6 months before signing the main ICF. If samples were obtained prior to the start of the most recent anticancer therapy, the Sponsor Medical Monitor should be consulted regarding the adequacy of the sample.

Exclusion criteria

Exclusion Criteria:

  • Has had prior treatment targeting mucin 1 (MUC1) or TA-MUC1.
  • Has spinal cord compression or clinically active central nervous system .
  • Has multiple primary , except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated, with no evidence of disease for ≥3 years.
  • Has any history of ILD/pneumonitis irrespective of use, or current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at Screening. Participants may be eligible if they had history of radiation pneumonitis that did not require steroids.
  • Has active or uncontrolled (HIV) infection.
  • Has evidence of active or uncontrolled virus or virus infection.
  • Any of the following within the past 6 months: cerebrovascular accident, , or other arterial thromboembolic event.
  • Has an active (ie, symptomatic and/or on-treatment), known, or suspected disease.
  • Current participation in other therapeutic procedures, except for participation in Long Term Follow-Up without any investigational treatment.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
590 participants (estimated)

Study arms

  • Experimental
    Dose Escalation (Part 1)

    Participants with locally advanced, metastatic, or unresectable tumors who will receive an intravenous (IV) infusion of DS-3939a starting at 1 mg/kg.

    Drug: DS-3939a

  • Experimental
    Dose Expansion (Part 2)

    Multiple expansion cohorts targeting various advanced solid tumors.

    Drug: DS-3939a

Interventions

  • DrugDS-3939a

    One IV infusion Q3W on Day 1 of each 21-day cycle

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose-limiting Toxicities Following Treatment With DS-3939a

    Time frame: Approximately 3 months after first dosing

  2. Overall Number of Participants with Treatment-emergent Adverse Events and Serious Adverse Events Following Treatment With DS-3939a

    Time frame: Up to approximately 31 months

  3. Number of Participants with Objective Response Rate Following Treatment With DS-3939a (Part 2)

    Time frame: Up to approximately 31 months

  4. PSA50 Response Rate Following Treatment with DS-3939a (Part 2; CRPC only)

    Time frame: Up to approximately 31 months

Secondary outcomes

  1. Number of Participants with Objective Response Rate Following Treatment With DS-3939a (Part 1)

    Time frame: Up to approximately 31 months

  2. Disease Control Rate Following Treatment With DS-3939a

    Time frame: Up to approximately 31 months

  3. Duration of Response Following Treatment With DS-3939a

    Time frame: Up to approximately 31 months

  4. Time to Response Following Treatment With DS-3939a

    Time frame: Up to approximately 31 months

  5. Progression Free Survival Following Treatment With DS-3939a

    Time frame: Up to approximately 31 months

  6. Overall Survival Following Treatment With DS-3939a

    Time frame: Up to approximately 31 months

  7. TA-MUC1 Expression by Immunohistochemistry Following Treatment With DS-3939a

    Time frame: At Cycle 1 Day 1

  8. Area Under the Plasma Concentration Curve (AUC) Following Treatment With DS-3939a

    Time frame: Cycles 1 & 3: Days 1, 2, 4, 8 & 15; Cycle 2: Day 1 & 1 time between Days 3 to 8 (Part 2 Only); Cycles 4 & every 2 cycles thereafter up to 31 months: Day 1 (each cycle is 21 days)

  9. Maximum Plasma Concentration (Cmax) Following Treatment With DS-3939a

    Time frame: Cycles 1 & 3: Days 1, 2, 4, 8 & 15; Cycle 2: Day 1 & 1 time between Days 3 to 8 (Part 2 Only); Cycles 4 & every 2 cycles thereafter up to 31 months: Day 1 (each cycle is 21 days)

  10. Time to Maximum Plasma Concentration (Tmax) Following Treatment With DS-3939a

    Time frame: Cycles 1 & 3: Days 1, 2, 4, 8 & 15; Cycle 2: Day 1 & 1 time between Days 3 to 8 (Part 2 Only); Cycles 4 & every 2 cycles thereafter up to 31 months: Day 1 (each cycle is 21 days)

  11. Minimum Observed Concentration (Ctrough) Following Treatment With DS-3939a

    Time frame: Cycles 1 & 3: Days 1, 2, 4, 8 & 15; Cycle 2: Day 1 & 1 time between Days 3 to 8 (Part 2 Only); Cycles 4 & every 2 cycles thereafter up to 31 months: Day 1 (each cycle is 21 days)

  12. Terminal Half-Life (T1/2) Following Treatment With DS-3939a

    Time frame: Cycles 1 & 3: Days 1, 2, 4, 8 & 15; Cycle 2: Day 1 & 1 time between Days 3 to 8 (Part 2 Only); Cycles 4 & every 2 cycles thereafter up to 31 months: Day 1 (each cycle is 21 days)

  13. Number of Participants With Treatment-emergent Anti-drug Antibodies Following Treatment With DS-3939a

    Time frame: Up to approximately 47 months

  14. PSA50 Response Rate Following Treatment with DS-3939a (Part 1; CRPC only)

    Time frame: Up to approximately 31 months

  15. PSA30 and PSA90 Response Rate Following Treatment with DS-3939a (CRPC only)

    Time frame: Up to approximately 31 months

  16. Time to PSA Progression Following Treatment with DS-3939a (CRPC only)

    Time frame: Up to approximately 31 months

  17. Radiographic Progression-free Survival (PCWG 3) Following Treatment with DS-3939a (CRPC only)

    Time frame: Up to approximately 31 months

  18. Overall Survival Following Treatment with DS-3939a (CRPC only)

    Time frame: Up to approximately 31 months

07

Study locations

43 of 61 sites recruiting
08

References and documents

Publications

  • Takano K, Yukiura M, Takahashi K, Kitamura M, Okuno H, Shiose Y, Honda K, Oyama K, Yamada M, Obuchi W, Kumagai K, Sakurai K, Goto R, Zembutsu A, Kagari T, Abe Y, Agatsuma T. DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. Mol Cancer Ther. 2026 Jan 2;25(1):7-20. doi: 10.1158/1535-7163.MCT-24-0666. PubMed 40635151 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Aug 2028, 59 months after the start.

Of 127 industry-sponsored phase 1/2 interventional studies under Neoplasm Metastasis, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 89. This study's planned 59 months is close to that.

Counting every sponsor, half of 213 studies reached it within 62 months; a quarter within 41 and three quarters within 89.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Oct 2026 → Aug 2028 and completion Feb 2027 → Nov 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2023
First posted
May 25, 2023
StartActual
Aug 18, 2023
Primary completionEst.
Aug 11, 2028was Oct 2026
CompletionEst.
Nov 11, 2028was Feb 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
26 sites added, 1 site removed. 5 sites changed recruiting status (4 now withdrawn, 1 now recruiting)
Show 5 sites
  • Florida Cancer Specialists · Sarasota, United StatesRecruiting→Withdrawn
  • McGill University Health Center · Montreal, CanadaNot yet recruiting→Withdrawn
  • Princess Margaret Cancer Center · Toronto, CanadaActive, not recruiting→Recruiting
  • Beijing Cancer Hospital · Beijing, ChinaNot yet recruiting→Withdrawn
  • Chu Strasbourg · Strasbourg, FranceRecruiting→Withdrawn
Show 26 added (10 China, 7 United States, 3 France, 3 Japan, 2 South Korea, 1 Spain)
  • Florida Cancer Specialists · Sarasota, United States
  • Piedmont Cancer Institute · Locust Grove, United States
  • Henry Ford Health System · Detroit, United States
  • Astera Cancer Care · East Brunswick, United States
  • Icahn School of Medicine Mt Sinai · New York, United States
  • Virginia Cancer Specialists · Fairfax, United States
  • The Medical College of Wisconsin, INC · Milwaukee, United States
  • Jilin Cancer Hospital · Changchun, China
  • Hunan Cancer Hospital · Changsha, China
  • Sichuan Cancer Hospital · Chengdu, China
  • Zhejiang Cancer Hospital · Hangzhou, China
  • The First Affiliated Hospital of Nanchang University · Nanchang, China
  • Tianjin Medical University Cancer Institute & Hospital · Tianjin, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
  • The First Affiliated Hospital of Xiâ An Jiaotong University · Xi'an, China
  • Xiangyang Central Hospital · Xiangyang, China
  • Centre Léon Bérard · Lyon, France
  • Ico - Site René Gauducheau · Saint-Herblain, France
  • Institut Claudius Regaud · Toulouse, France
  • Saiseikai Kumamoto Hospital · Kumamoto, Japan
  • Nho Hokkaido Cancer Center · Sapporo, Japan
  • Shizuoka Cancer Center · Sunto-gun, Japan
  • National Cancer Center · Goyang, South Korea
  • Seoul National University Bundang Hospital · Seongnam-si, South Korea
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • The First Affiliated Hospital of Xiâan Jiaotong University · Xi'an, China
Show 1 removed
  • The First Affiliated Hospital of Xiâ An Jiaotong University · Xi'an, China
across 2 updates, Sep 29, 2026 – Oct 15, 2026
Primary completion
Oct 20, 2026→Aug 11, 2028
Oct 15, 2026
Study completion
Feb 15, 2027→Nov 11, 2028
Oct 15, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Florida Cancer Specialists · Sarasota, United StatesContact removed (no phone or email listed)
  • Institut Claudius Regaud · Toulouse, FranceContact added (no phone or email listed)
Sep 29, 2026
Show all 2 updates
  1. Oct 15, 2026
    1 site added, 1 site removed
    Show site
    • The First Affiliated Hospital of Xiâan Jiaotong University · Xi'an, China
    Show 1 removed
    • The First Affiliated Hospital of Xiâ An Jiaotong University · Xi'an, China
    Primary completion Oct 20, 2026→Aug 11, 2028
    Study completion Feb 15, 2027→Nov 11, 2028
    + 1 other change: verification date
  2. Sep 29, 2026
    25 sites added. 5 sites changed recruiting status (4 now withdrawn, 1 now recruiting)
    Show 5 sites
    • Florida Cancer Specialists · Sarasota, United StatesRecruiting→Withdrawn
    • McGill University Health Center · Montreal, CanadaNot yet recruiting→Withdrawn
    • Princess Margaret Cancer Center · Toronto, CanadaActive, not recruiting→Recruiting
    • Beijing Cancer Hospital · Beijing, ChinaNot yet recruiting→Withdrawn
    • Chu Strasbourg · Strasbourg, FranceRecruiting→Withdrawn
    Show 25 added (9 China, 7 United States, 3 France, 3 Japan, 2 South Korea, 1 Spain)
    • Florida Cancer Specialists · Sarasota, United States
    • Piedmont Cancer Institute · Locust Grove, United States
    • Henry Ford Health System · Detroit, United States
    • Astera Cancer Care · East Brunswick, United States
    • Icahn School of Medicine Mt Sinai · New York, United States
    • Virginia Cancer Specialists · Fairfax, United States
    • The Medical College of Wisconsin, INC · Milwaukee, United States
    • Jilin Cancer Hospital · Changchun, China
    • Hunan Cancer Hospital · Changsha, China
    • Sichuan Cancer Hospital · Chengdu, China
    • Zhejiang Cancer Hospital · Hangzhou, China
    • The First Affiliated Hospital of Nanchang University · Nanchang, China
    • Tianjin Medical University Cancer Institute & Hospital · Tianjin, China
    • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
    • The First Affiliated Hospital of Xiâ An Jiaotong University · Xi'an, China
    • Xiangyang Central Hospital · Xiangyang, China
    • Centre Léon Bérard · Lyon, France
    • Ico - Site René Gauducheau · Saint-Herblain, France
    • Institut Claudius Regaud · Toulouse, France
    • Saiseikai Kumamoto Hospital · Kumamoto, Japan
    • Nho Hokkaido Cancer Center · Sapporo, Japan
    • Shizuoka Cancer Center · Sunto-gun, Japan
    • National Cancer Center · Goyang, South Korea
    • Seoul National University Bundang Hospital · Seongnam-si, South Korea
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Florida Cancer Specialists · Sarasota, United StatesContact removed (no phone or email listed)
    • Institut Claudius Regaud · Toulouse, FranceContact added (no phone or email listed)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05875168
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
May 25, 2023
Start date
Aug 18, 2023
Primary completion
Aug 11, 2028 (estimated)
Completion
Nov 11, 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

(US Sites) Daiichi Sankyo Contact for Clinical Trial Information
Contact
CTRinfo@dsi.com
908-992-6400
(Asia Sites) Daiichi Sankyo Contact for Clinical Trial Information
Contact
dsclinicaltrial_jp@daiichisankyo.com
+81-3-6225-1111 (M-F 9-5 JST)
Global Clinical Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion